Sign in
CompletedNo phase

Longitudinal Observational Biomarker Study

Key facts

Who runs it
Centre for Addiction and Mental Health
Where
Los Angeles, New York, Pittsburgh, and St Louis, United StatesSee the 4 sitesAlso in 1 other country, 1 site
Trial code
Status
Completed
People taking part
506 people enrolled
Started
27 Sept 2017
Ended
31 Jul 2024
Type of study
Observational
Treatments tested
  • Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)
  • Neuropsychological Data
  • Clinical Scales
Record updated
25 November 2024

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Men and women aged 60 and older
  • Current Major Depressive Disorder (MDD)
  • Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length
  • Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher

Who cannot take part

  • Dementia
  • Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
  • Non-correctable, clinically significant sensory impairment interfering with participation
  • Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management
  • Moderate to severe substance or alcohol use disorder
  • Seizure disorder
  • Parkinson's Disease
  • High risk for suicide and unable to be managed safely in the clinical trial
  • Individuals with any contraindications to MRI

Where in United States

Also in 1 other country, 1 site

  • UCLA Late-Life Mood, Stress, and Wellness Research ProgramLos Angeles, United States
  • Columbia University Adult and Late Life Depression ClinicNew York, United States
  • UPMC Late-Life Depression, Evaluation, Prevention, and Treatment ProgramPittsburgh, United States
  • Washington University School of Medicine Healthy Mind LabSt Louis, United States

About the trial

What the trial wants to find out

The purpose of this study is to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.

Treatments tested

  • Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI)
  • Neuropsychological Data
  • Clinical Scales

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro Study)
Record updated
25 November 2024